特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
934455

デュシェンヌ型筋ジストロフィー (DMD) 治療薬の世界市場:規模・現状・予測 (2020~2026年)

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Status and Forecast 2020-2026

出版日: | 発行: QYResearch | ページ情報: 英文 75 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.40円
デュシェンヌ型筋ジストロフィー (DMD) 治療薬の世界市場:規模・現状・予測 (2020~2026年)
出版日: 2020年09月16日
発行: QYResearch
ページ情報: 英文 75 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のデュシェンヌ型筋ジストロフィー (DMD) 治療薬の市場規模は、2019年には6億7214万米ドル、2026年には77億0193万米ドルと、42.10%のCAGRで成長していく、と予測されています。

当レポートでは、世界のデュシェンヌ型筋ジストロフィー (DMD) 治療薬の市場について分析し、業界の基本構造や背景事情・最新情勢、全体的な市場動向の見通し (過去5年間・今後7年間分)、種類別・地域別の詳細動向、企業間の競争状態 (市場シェア構造)、主要企業のプロファイルと業績動向などについて調査しております。

第1章 分析概要

  • 分析範囲
  • 市場の主な区分
  • 分析対象企業:収益額ランキング
  • 種類別の市場区分
    • EXONDYS
    • Emflaza
    • Translarna
  • 用途別の市場区分
    • 病院
    • クリニック
    • 在宅治療
  • 分析対象
  • 分析期間

第2章 世界市場の成長動向:地域別

  • デュシェンヌ型筋ジストロフィー (DMD) 治療薬市場の将来展望(2015~2026年)
  • 成長動向:地域別
    • 市場規模:地域別 (2015/2021/2026年)
    • 市場シェア:地域別、実績値 (2015~2020年)
    • 市場規模:地域別、予測値 (2021~2026年)
  • 業界の動向と成長戦略
    • 市場の主な動向
    • 市場促進要因
    • 市場の課題
    • ポーターのファイブフォース分析
    • DMD治療薬市場の成長戦略

第3章 DMD治療薬の研究状況

  • 遺伝子治療
  • エクソンスキッピング
  • 筋肉強化
  • 筋肉修復加速
  • 筋肉炎症治療
  • ジストロフィン欠乏心臓の保護

第4章 競争環境:主要企業別

  • DMD治療薬の大手企業:市場規模
    • 市場収益額:企業別 (2015~2020年)
    • 市場シェア:企業別 (2015~2020年)
    • 市場シェア:企業の種類別(ティア1、ティア2、ティア3)
  • DMD治療薬市場の集中度
  • 主要企業の本社所在地・販売エリア
  • 主要企業の主力製品・ソリューション・サービス
  • 主要企業の創設時期
  • 企業合併・買収 (M&A)/事業拡張計画

第5章 市場データ:種類別の内訳 (2015~2026年)

第6章 市場データ:用途別の内訳 (2015~2026年)

  • 市場規模:用途別、実績値 (2015~2020年)
  • 市場規模:用途別、予測値 (2021~2026年)

第7章 北米

  • 市場規模(2015~2026年)
  • 主要企業の動向
  • 市場規模:種類別、実績値 (2015~2020年)
  • 市場規模:用途別、実績値 (2015~2020年)

第8章 欧州

第9章 主要企業のプロフィール

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

第10章 バリューチェーン・販売チャネルの分析

  • バリューチェーン分析
  • 販売チャネル分析
    • DMD治療薬の販売チャネル
  • DMD治療薬の顧客

第11章 アナリストの見解/結論

第12章 付録

図表

List of Tables and Figures

  • Table 1. Recommended treatments way for Duchenne Muscular Dystrophy
  • Table 2. Duchenne Muscular Dystrophy (DMD) Therapeutics Key Market Segments
  • Table 3. Key Players Covered: Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
  • Table 4. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
  • Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2015 VS 2019
  • Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
  • Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
  • Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
  • Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Regions (2015-2020)
  • Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
  • Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Regions (2021-2026)
  • Table 12. Market Top Trends
  • Table 13. Key Drivers: Impact Analysis
  • Table 14. Key Challenges
  • Table 15. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Strategy
  • Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2015-2019) (US$ Million)
  • Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2015-2019)
  • Table 18. Global Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (HHI) (2015-2019)
  • Table 19. Key Players Headquarters and Area Served
  • Table 20. Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
  • Table 21. Establish Date of Duchenne Muscular Dystrophy (DMD) Therapeutics Market Player
  • Table 22. Mergers & Acquisitions, Expansion Plans
  • Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2015-2019) (US$ Million)
  • Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2015-2019)
  • Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2015-2020) (US$ Million)
  • Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2015-2020)
  • Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2021-2026) (US$ Million)
  • Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021-2026)
  • Table 29. North America Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2019) (US$ Million)
  • Table 30. North America Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share in 2019
  • Table 31. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2015-2019) (US$ Million)
  • Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2015-2020)
  • Table 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2015-2019) (US$ Million)
  • Table 34. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2015-2020)
  • Table 35. Europe Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2019 (US$ Million)
  • Table 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2015-2019) (US$ Million)
  • Table 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2015-2020)
  • Table 38. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2015-2019) (US$ Million)
  • Table 39. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2015-2020)
  • Table 40. Sarepta Therapeutics Company Details
  • Table 41. Sarepta Therapeutics Business Overview
  • Table 42. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
  • Table 43. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2015-2019) (US$ Million)
  • Table 44. Sarepta Therapeutics Recent Development
  • Table 45. PTC Therapeutics Company Details
  • Table 46. PTC Therapeutics Business Overview
  • Table 47. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
  • Table 48. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2015-2020) (US$ Million)
  • Table 49. PTC Therapeutics Recent Development
  • Table 50. Pfizer Company Details
  • Table 51. Pfizer Business Overview
  • Table 52. Bristol-Myers Squibb Company Details
  • Table 53. Bristol-Myers Squibb Business Overview
  • Table 54. Italfarmaco Company Details
  • Table 55. Italfarmaco Business Overview
  • Table 56. Santhera Pharmaceuticals Company Details
  • Table 57. Santhera Pharmaceuticals Business Overview
  • Table 58. Duchenne Muscular Dystrophy (DMD) Therapeutics Customers List
  • Table 59. Research Programs/Design for This Report
  • Table 60. Key Data Information from Secondary Sources
  • Table 61. Key Data Information from Primary Sources
  • Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Picture
  • Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2019
  • Figure 3. EXONDYS Features
  • Figure 4. Emflaza Features
  • Figure 5. Translarna Features
  • Figure 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2019 VS 2026
  • Figure 7. Hospitals Case Studies
  • Figure 8. Clinics Case Studies
  • Figure 9. Home Care Case Studies
  • Figure 10. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
  • Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
  • Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Regions: 2020 VS 2026
  • Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Regions (2021-2026)
  • Figure 14. Porter's Five Forces Analysis
  • Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2019
  • Figure 16. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2015-2026) (US$ Million)
  • Figure 17. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2015-2026) (US$ Million)
  • Figure 18. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2015-2020)
  • Figure 19. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2015-2020)
  • Figure 20. Duchenne Muscular Dystrophy (DMD) Therapeutics Value Chain
  • Figure 21. Channels of Distribution
  • Figure 22. Bottom-up and Top-down Approaches for This Report
  • Figure 23. Data Triangulation
  • Figure 24. Key Executives Interviewed 63
目次

Market Analysis and Insights: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market

In 2019, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was US$ 672.14 million and it is expected to reach US$ 7701.93 million by the end of 2026, with a CAGR of 42.10% during 2020-2026.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Scope and Market Size

Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented by players, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

By Company

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Segment by Type

  • EXONDYS
  • Emflaza
  • Translarna

Segment by Application

  • Hospitals
  • Clinics
  • Home Care

By Region

  • North America
  • Europe
  • Japan
  • Other Region

TABLE OF CONTENTS

1 REPORT OVERVIEW

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2015 VS 2019
    • 1.4.2 EXONDYS
    • 1.4.3 Emflaza
    • 1.4.4 Translarna
  • 1.5 Market by Application
    • 1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Home Care
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 GLOBAL GROWTH TRENDS

  • 2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2015-2026)
  • 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Regions
    • 2.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Regions (2015-2020)
    • 2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter's Five Forces Analysis
    • 2.3.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Strategy

3 DMD THERAPY RESEARCH STATUS

  • 3.1 Gene Therapy
  • 3.2 Exon skipping
  • 3.3 Muscle Strengthen
  • 3.4 Accelerating Muscle Repair
  • 3.5 Combating Inflammation in Muscle
  • 3.6 Protecting the Dystrophin-Deficient Heart

4 COMPETITION LANDSCAPE BY KEY PLAYERS

  • 4.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Market Size
    • 4.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
    • 4.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players
  • 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
  • 4.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Area Served
  • 4.4 Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
  • 4.5 Establish Date of Duchenne Muscular Dystrophy (DMD) Therapeutics Market Player
  • 4.6 Mergers & Acquisitions, Expansion Plans

5 DUCHENNE MUSCULAR DYSTROPHY (DMD) THERAPEUTICS BREAKDOWN DATA BY TYPE (2015-2026)

6 DUCHENNE MUSCULAR DYSTROPHY (DMD) THERAPEUTICS BREAKDOWN DATA BY APPLICATION(2015-2026)

  • 6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2015-2020)
  • 6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2021-2026)

7 NORTH AMERICA

  • 7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2015-2026)
  • 7.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players in North America
  • 7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  • 7.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

8 EUROPE

  • 8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2015-2026)
  • 8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players in Europe
  • 8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  • 8.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2015-2019)

9 KEY PLAYERS PROFILES

  • 9.1 Sarepta Therapeutics
    • 9.1.1 Sarepta Therapeutics Company Details
    • 9.1.2 Sarepta Therapeutics Business Overview
    • 9.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
    • 9.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2015-2019)
    • 9.1.5 Sarepta Therapeutics Recent Development
  • 9.2 PTC Therapeutics
    • 9.2.1 PTC Therapeutics Company Details
    • 9.2.2 PTC Therapeutics Business Overview
    • 9.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
    • 9.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2015-2020)
    • 9.2.5 PTC Therapeutics Recent Development
  • 9.3 Pfizer
    • 9.3.1 Pfizer Company Details
    • 9.3.2 Pfizer Business Overview
    • 9.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
  • 9.4 Bristol-Myers Squibb
    • 9.4.1 Bristol-Myers Squibb Company Details
    • 9.4.2 Bristol-Myers Squibb Business Overview
    • 9.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
  • 9.5 Italfarmaco
    • 9.5.1 Italfarmaco Company Details
    • 9.5.2 Italfarmaco Business Overview
    • 9.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
  • 9.6 Santhera Pharmaceuticals
    • 9.6.1 Santhera Pharmaceuticals Company Details
    • 9.6.2 Santhera Pharmaceuticals Business Overview
    • 9.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

10 VALUE CHAIN AND SALES CHANNELS ANALYSIS

  • 10.1 Value Chain Analysis
  • 10.2 Sales Channels Analysis
    • 10.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Channels
  • 10.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Customers

11 ANALYST'S VIEWPOINTS/CONCLUSIONS

12 APPENDIX

  • 12.1 Research Methodology
    • 12.1.1 Methodology/Research Approach
    • 12.1.2 Data Source
  • 12.2 Disclaimer
  • 12.3 Author Details
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.